TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MariMed ( (MRMD) ) has issued an announcement.
MariMed Inc.’s brand, Betty’s Eddies™, has launched a new limited-edition winter seasonal fruit chew called Bundle Up Betty’s, featuring cranberry, orange, and warming spices. This product, infused with THC and CBD, is available in select dispensaries across Massachusetts, Maryland, Illinois, and Delaware, aiming to provide consumers with a comforting and relaxing experience during the winter season.
The most recent analyst rating on (MRMD) stock is a Buy with a $0.25 price target. To see the full list of analyst forecasts on MariMed stock, see the MRMD Stock Forecast page.
Spark’s Take on MRMD Stock
According to Spark, TipRanks’ AI Analyst, MRMD is a Underperform.
MariMed’s overall stock score is low due to significant financial challenges, bearish technical indicators, and poor valuation metrics. While there are some positive aspects, such as revenue growth and strategic expansion, the risks outweigh the strengths.
To see Spark’s full report on MRMD stock, click here.
More about MariMed
MariMed Inc. is a prominent multi-state cannabis operator known for its state-of-the-art cultivation, production, and retail facilities. The company boasts an award-winning portfolio of cannabis brands, including Betty’s Eddies™, which is recognized for its quality and innovation across the country.
Average Trading Volume: 1,719,765
Technical Sentiment Signal: Strong Sell
Current Market Cap: $33.3M
Learn more about MRMD stock on TipRanks’ Stock Analysis page.